Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
1 November 1998 | Volume 129 Issue 9 | Pages 681-689
Background: A majority of all myocardial infarctions occur in patients who are 65 years of age or older and have average cholesterol levels, but little information is available on whether cholesterol lowering in such patients reduces the rate of recurrent cardiovascular disease.
Objective: To determine whether pravastatin reduces the rate of recurrent cardiovascular events in older patients.
Design: Subset analysis of a randomized, controlled trial.
Setting: 80 hospitals and affiliates in the United States and Canada.
Patients: 1283 patients aged 65 to 75 years who had had myocardial infarction and had a plasma total cholesterol level less than 6.2 mmol/L (240 mg/dL) and a low-density lipoprotein cholesterol level of 3.0 to 4.5 mmol/L (115 to 174 mg/dL).
Intervention: Pravastatin, 40 mg/d, or placebo.
Measurements: Five-year event rates of major coronary events (coronary death, nonfatal myocardial infarction, angioplasty, or bypass surgery) and stroke.
Results: Major coronary events occurred in 28.1% of placebo recipients and 19.7% of pravastatin recipients (difference, 9.0 percentage points [95% CI, 4 to 13 percentage points]; relative risk reduction, 32%; P < 0.001). Coronary death occurred in 10.3% of the placebo group and in 5.8% of the pravastatin group (difference, 4.6 percentage points [CI, 1.9 to 6.5 percentage points]; relative risk reduction, 45%; P = 0.004). Stroke incidence was 7.3% in the placebo group and 4.5% in the pravastatin group (absolute reduction, 2.9 percentage points [CI, 0.3 to 4.5 percentage points]; relative reduction, 40%; P = 0.03). The numbers of older patients needed to treat for 5 years were 11 (CI, 8 to 24) to prevent a major coronary event and 22 (CI, 15 to 53) to prevent a coronary death. For every 1000 older patients treated, 225 cardiovascular hospitalizations would be prevented compared with 121 hospitalizations in 1000 younger patients.
Conclusions: In older patients with myocardial infarction and cholesterol levels in the average range, pravastatin is associated with a clinically important reduction in risk for major coronary events and stroke. Given the high cardiovascular event rate in older patients, the potential for absolute benefit in this age group is substantial.
Author and Article Information
For the CARE Investigators
ARTICLE
Effect of Pravastatin on Cardiovascular Events in Older Patients with Myocardial Infarction and Cholesterol Levels in the Average Range: Results of the Cholesterol and Recurrent Events (CARE) Trial
![]()
For author affiliations and current author addresses, see end of text.
Grant Support: By an investigator-initiated grant from Bristol-Myers Squibb.
Requests for Reprints: Sandra J. Lewis, MD, Legacy Health System, Portland Cardiovascular Institute, 2222 NW Lovejoy Street, Portland, OR 97210.
Current Author Addresses: Dr. Lewis: Legacy Health System, Portland Cardiovascular Institute, 2222 NW Lovejoy Street, Portland, OR 97210.
Related articles in Annals:
This article has been cited by other articles:
![]() |
J. Afilalo, G. Duque, R. Steele, J. W. Jukema, A. J.M. de Craen, and M. J. Eisenberg Statins for secondary prevention in elderly patients: a hierarchical bayesian meta-analysis. J. Am. Coll. Cardiol., January 1, 2008; 51(1): 37 - 45. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. G. P. Roberts, E. Guallar, and A. Rodriguez Efficacy and Safety of Statin Monotherapy in Older Adults: A Meta-Analysis J. Gerontol. A Biol. Sci. Med. Sci., August 1, 2007; 62(8): 879 - 887. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. K. Wenger, S. J. Lewis, D. M. Herrington, V. Bittner, F. K. Welty, and for the Treating to New Targets Study Steering Com Outcomes of Using High- or Low-Dose Atorvastatin in Patients 65 Years of Age or Older with Stable Coronary Heart Disease Ann Intern Med, July 3, 2007; 147(1): 1 - 9. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Schneeweiss, A. R. Patrick, M. Maclure, C. R. Dormuth, and R. J. Glynn Adherence to Statin Therapy Under Drug Cost Sharing in Patients With and Without Acute Myocardial Infarction: A Population-Based Natural Experiment Circulation, April 24, 2007; 115(16): 2128 - 2135. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. G. Ray, C. M. Norris, J. A. Udell, R. T. Tsuyuki, F. A. McAlister, M. L. Knudtson, and W. A. Ghali Lipid-Lowering Therapy and Outcomes in Heart Failure Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2007; 12(1): 27 - 35. [Abstract] [PDF] |
||||
![]() |
K. K. Khush, D. D. Waters, V. Bittner, P. C. Deedwania, J. J.P. Kastelein, S. J. Lewis, and N. K. Wenger Effect of High-Dose Atorvastatin on Hospitalizations for Heart Failure: Subgroup Analysis of the Treating to New Targets (TNT) Study Circulation, February 6, 2007; 115(5): 576 - 583. [Abstract] [Full Text] [PDF] |
||||
![]() |
Heart Protection Study Collaborative Group,* N-Terminal Pro-B-Type Natriuretic Peptide, Vascular Disease Risk, and Cholesterol Reduction Among 20,536 Patients in the MRC/BHF Heart Protection Study J. Am. Coll. Cardiol., January 23, 2007; 49(3): 311 - 319. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Selvin, J. Coresh, and F. L. Brancati The burden and treatment of diabetes in elderly individuals in the u.s. Diabetes Care, November 1, 2006; 29(11): 2415 - 2419. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. K. Ray, R. G. Bach, C. P. Cannon, R. Cairns, A. J. Kirtane, S. D. Wiviott, C. H. McCabe, E. Braunwald, C. M. Gibson, and for the PROVE IT-TIMI 22 Investigators Benefits of achieving the NCEP optional LDL-C goal among elderly patients with ACS Eur. Heart J., October 1, 2006; 27(19): 2310 - 2316. [Abstract] [Full Text] [PDF] |
||||
![]() |
E S Houslay, S J Cowell, R J Prescott, J Reid, J Burton, D B Northridge, N A Boon, D E Newby, and on behalf of the Scottish Aortic Stenosis and Lipi Progressive coronary calcification despite intensive lipid-lowering treatment: a randomised controlled trial Heart, September 1, 2006; 92(9): 1207 - 1212. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Kronzon and P. A. Tunick Aortic Atherosclerotic Disease and Stroke Circulation, July 4, 2006; 114(1): 63 - 75. [Full Text] [PDF] |
||||
![]() |
Prepared by: British Cardiac Society, British Hype JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice Heart, December 1, 2005; 91(suppl_5): v1 - v52. [Full Text] [PDF] |
||||
![]() |
Developed in Collaboration With the American Colle, Endorsed by the Heart Rhythm Society, S. A. Hunt, W. T. Abraham, M. H. Chin, A. M. Feldman, G. S. Francis, T. G. Ganiats, M. Jessup, M. A. Konstam, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult--Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure) J. Am. Coll. Cardiol., September 20, 2005; 46(6): 1116 - 1143. [Full Text] [PDF] |
||||
![]() |
S. A. Hunt, W. T. Abraham, M. H. Chin, A. M. Feldman, G. S. Francis, T. G. Ganiats, M. Jessup, M. A. Konstam, D. M. Mancini, K. Michl, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult--Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): Developed in Collaboration With the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: Endorsed by the Heart Rhythm Society Circulation, September 20, 2005; 112(12): 1825 - 1852. [Full Text] [PDF] |
||||
![]() |
D. M. Eddy, L. Schlessinger, and R. Kahn Clinical Outcomes and Cost-Effectiveness of Strategies for Managing People at High Risk for Diabetes Ann Intern Med, August 16, 2005; 143(4): 251 - 264. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. S. Aronow Should the NCEP III Guidelines Be Changed in Elderly and Younger Persons at High Risk for Cardiovascular Events? J. Gerontol. A Biol. Sci. Med. Sci., May 1, 2005; 60(5): 591 - 592. [Full Text] [PDF] |
||||
![]() |
L. H. Smith, M. S. Petrie, J. D. Morrow, J. A. Oates, and D. E. Vaughan The sterol response element binding protein regulates cyclooxygenase-2 gene expression in endothelial cells J. Lipid Res., May 1, 2005; 46(5): 862 - 871. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. S. Aronow Management of the Elderly Person After Myocardial Infarction J. Gerontol. A Biol. Sci. Med. Sci., November 1, 2004; 59(11): 1173 - 1185. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Thompson and N. J Temple The case for statins: has it really been made? J R Soc Med, October 1, 2004; 97(10): 461 - 464. [Full Text] [PDF] |
||||
![]() |
D. C Bjornson Interpretation of Drug Risk and Benefit: Individual and Population Perspectives Ann. Pharmacother., April 1, 2004; 38(4): 694 - 699. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J Everly, P. C Heaton, and R. J Cluxton Jr {beta}-Blocker Underuse in Secondary Prevention of Myocardial Infarction Ann. Pharmacother., February 1, 2004; 38(2): 286 - 293. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. A Dornbrook-Lavender, M. T Roth, and J. A Pieper Secondary Prevention of Coronary Heart Disease in the Elderly Ann. Pharmacother., December 1, 2003; 37(12): 1867 - 1876. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. M. Eddy and L. Schlessinger Validation of the Archimedes Diabetes Model Diabetes Care, November 1, 2003; 26(11): 3102 - 3110. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Ghosh and W. S. Aronow Utilization of Lipid-Lowering Drugs in Elderly Persons With Increased Serum Low-Density Lipoprotein Cholesterol Associated With Coronary Artery Disease, Symptomatic Peripheral Arterial Disease, Prior Stroke, or Diabetes Mellitus Before and After an Educational Program on Dyslipidemia Treatment J. Gerontol. A Biol. Sci. Med. Sci., May 1, 2003; 58(5): M432 - 435. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. A. Allen Maycock, J. B. Muhlestein, B. D. Horne, J. F. Carlquist, T. L. Bair, R. R. Pearson, Q. Li, J. L. Anderson, and Intermountain Heart Collaborative Study Statin therapy is associated with reduced mortality across all age groups of individuals with significant coronary disease, including very elderly patients J. Am. Coll. Cardiol., November 20, 2002; 40(10): 1777 - 1785. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. O. Fedder, C. E. Koro, G. J. L'Italien, A. M. Gotto Jr, and L. H. Kuller Primary Prevention Lipid-Lowering Drug Therapy * Response Circulation, August 13, 2002; 106 (7): e35 - e36. [Full Text] [PDF] |
||||
![]() |
J. S. Benner, R. J. Glynn, H. Mogun, P. J. Neumann, M. C. Weinstein, and J. Avorn Long-term Persistence in Use of Statin Therapy in Elderly Patients JAMA, July 24, 2002; 288(4): 455 - 461. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. B. Applegate Elderly Patients' Adherence to Statin Therapy JAMA, July 24, 2002; 288(4): 495 - 497. [Full Text] [PDF] |
||||
![]() |
W. S. Aronow Guest Editorial: Should Hypercholesterolemia in Older Persons Be Treated to Reduce Cardiovascular Events? J. Gerontol. A Biol. Sci. Med. Sci., July 1, 2002; 57(7): M411 - 413. [Full Text] |
||||
![]() |
J. Z. Ayanian, M. B. Landrum, and B. J. McNeil Use of Cholesterol-Lowering Therapy by Elderly Adults After Myocardial Infarction Arch Intern Med, May 13, 2002; 162(9): 1013 - 1019. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. S. Aronow, C. Ahn, and H. Gutstein Incidence of New Atherothrombotic Brain Infarction in Older Persons With Prior Myocardial Infarction and Serum Low-Density Lipoprotein Cholesterol >=125 mg/dl Treated With Statins Versus No Lipid-Lowering Drug J. Gerontol. A Biol. Sci. Med. Sci., May 1, 2002; 57(5): M333 - 335. [Abstract] [Full Text] |
||||
![]() |
M. A. Williams, J. L. Fleg, P. A. Ades, B. R. Chaitman, N. H. Miller, S. M. Mohiuddin, I. S. Ockene, C. B. Taylor, and N. K. Wenger Secondary Prevention of Coronary Heart Disease in the Elderly (With Emphasis on Patients >=75 Years of Age): An American Heart Association Scientific Statement From the Council on Clinical Cardiology Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention Circulation, April 9, 2002; 105(14): 1735 - 1743. [Full Text] [PDF] |
||||
![]() |
O. Faergeman Estimation and reduction of cardiovascular risk in old people Eur. Heart J., February 2, 2002; 23(4): 261 - 263. [Full Text] [PDF] |
||||
![]() |
R. A. Kreisberg and A. Oberman Lipids and Atherosclerosis: Lessons Learned from Randomized Controlled Trials of Lipid Lowering and Other Relevant Studies J. Clin. Endocrinol. Metab., February 1, 2002; 87(2): 423 - 437. [Full Text] [PDF] |
||||
![]() |
J. H. Stein, C. M. Carlsson, K. Papcke-Benson, S. E. Aeschlimann, A. Bodemer, M. Carnes, and P. E. McBride The effects of lipid-lowering and antioxidant vitamin therapies on flow-mediated vasodilation of the brachial artery in older adults with hypercholesterolemia J. Am. Coll. Cardiol., December 1, 2001; 38(7): 1806 - 1813. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Gaw Healthy ageing: addressing acute coronary syndrome? Eur. Heart J. Suppl., November 1, 2001; 3(suppl_N): N11 - N15. [Abstract] [PDF] |
||||
![]() |
J. C. LaRosa Prevention and Treatment of Coronary Heart Disease: Who Benefits? Circulation, October 2, 2001; 104(14): 1688 - 1692. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. H. Davidson Treatment of the Elderly with 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors: Focus on Drug Interactions Journal of Cardiovascular Pharmacology and Therapeutics, September 1, 2001; 6(3): 219 - 229. [Abstract] [PDF] |
||||
![]() |
N. Kagansky, S. Levy, Y. Berner, E. Rimon, and H. Knobler Cholesterol lowering in the older population: time for reassessment? QJM, September 1, 2001; 94(9): 457 - 463. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. B. Braunstein, A. Cheng, G. Cohn, M. Aggarwal, C. M. Nass, and R. S. Blumenthal Lipid Disorders : Justification of Methods and Goals of Treatment Chest, September 1, 2001; 120(3): 979 - 988. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Yarzebski, F. Spencer, R. J. Goldberg, D. Lessard, and J. M. Gore Temporal Trends (1986-1997) in Cholesterol Level Assessment and Management Practices in Patients With Acute Myocardial Infarction: A Population-Based Perspective Arch Intern Med, June 25, 2001; 161(12): 1521 - 1528. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. G. Ray, M. Mamdani, R. T. Tsuyuki, D. R. Anderson, E. L. Yeo, and A. Laupacis Use of Statins and the Subsequent Development of Deep Vein Thrombosis Arch Intern Med, June 11, 2001; 161(11): 1405 - 1410. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Hunt, P. Young, J. Simes, W. Hague, S. Mann, D. Owensby, G. Lane, A. Tonkin, and for the LIPID Investigators Benefits of Pravastatin on Cardiovascular Events and Mortality in Older Patients with Coronary Heart Disease Are Equal to or Exceed Those Seen in Younger Patients: Results from the LIPID Trial Ann Intern Med, May 15, 2001; 134(10): 931 - 940. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Malach, J. Quinley, P. J. Imperato, and M. Wallen Improving Lipid Evaluation and Management in Medicare Patients Hospitalized for Acute Myocardial Infarction Arch Intern Med, March 26, 2001; 161(6): 839 - 844. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Bandyopadhyay, A.J. Bayer, and M.S. O'Mahony Age and gender bias in statin trials QJM, March 1, 2001; 94(3): 127 - 132. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. S. Aronow Treatment of Older Persons With Hypercholesterolemia With and Without Cardiovascular Disease J. Gerontol. A Biol. Sci. Med. Sci., March 1, 2001; 56(3): 138M - 145. [Abstract] [Full Text] |
||||
![]() |
S. Recent advances: Geriatric BMJ, January 13, 2001; 322(7278): 86 - 89. [Full Text] [PDF] |
||||
![]() |
B. R. Chaitman and S. R. Bitar Is ST segment elevation non-Q- wave myocardial infarction after thrombolytic therapy a new clinical entity that requires an invasive management strategy? J. Am. Coll. Cardiol., January 1, 2001; 37(1): 26 - 29. [Full Text] [PDF] |
||||
![]() |
M. H. Davidson, K. C. Maki, P. Marx, A. C. Maki, M. S. Cyrowski, N. Nanavati, and J.-C. Arce Effects of Continuous Estrogen and Estrogen-Progestin Replacement Regimens on Cardiovascular Risk Markers in Postmenopausal Women Arch Intern Med, November 27, 2000; 160(21): 3315 - 3325. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Lye and C. Donnellan GENERAL CARDIOLOGY: Heart disease in the elderly Heart, November 1, 2000; 84(5): 560 - 566. [Full Text] |
||||
![]() |
A. Sgadari, R. A. Incalzi, G. Onder, C. Pedone, and G. Gambassi Lipid-Lowering Therapy in Patients With Coronary Artery Disease: Sex or Age Bias? Arch Intern Med, September 25, 2000; 160(17): 2684 - 2685. [Full Text] [PDF] |
||||
![]() |
C.G. Isles and J.R. Paterson Identifying patients at risk for coronary heart disease: implications from trials of lipid-lowering drug therapy QJM, September 1, 2000; 93(9): 567 - 574. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. A. Ganz, K. M. Kuntz, G. A. Jacobson, and J. Avorn Cost-Effectiveness of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor Therapy in Older Patients with Myocardial Infarction Ann Intern Med, May 16, 2000; 132(10): 780 - 787. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. C. Hess, A. M. Demchuk, L. M. Brass, and F. M. Yatsu HMG-CoA reductase inhibitors (statins): A promising approach to stroke prevention Neurology, February 22, 2000; 54(4): 790 - 796. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. C. LaRosa, J. He, and S. Vupputuri Effect of Statins on Risk of Coronary Disease: A Meta-analysis of Randomized Controlled Trials JAMA, December 22, 1999; 282(24): 2340 - 2346. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. J. Ansell, K. E. Watson, and A. M. Fogelman An Evidence-Based Assessment of the NCEP Adult Treatment Panel II Guidelines JAMA, December 1, 1999; 282(21): 2051 - 2057. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. M. Landau Is Cholesterol a Risk Factor for Stroke?: No Arch Neurol, December 1, 1999; 56(12): 1521 - 1524. [Full Text] [PDF] |
||||
![]() |
S. M. G |